120 related articles for article (PubMed ID: 38303260)
21. Three-arm phase III trial comparing cisplatin plus 5-FU (CF) versus docetaxel, cisplatin plus 5-FU (DCF) versus radiotherapy with CF (CF-RT) as preoperative therapy for locally advanced esophageal cancer (JCOG1109, NExT study).
Nakamura K; Kato K; Igaki H; Ito Y; Mizusawa J; Ando N; Udagawa H; Tsubosa Y; Daiko H; Hironaka S; Fukuda H; Kitagawa Y;
Jpn J Clin Oncol; 2013 Jul; 43(7):752-5. PubMed ID: 23625063
[TBL] [Abstract][Full Text] [Related]
22. Early administration of pegfilgrastim for esophageal cancer treated with docetaxel, cisplatin, and fluorouracil: A phase II study.
Ishikawa T; Yasuda T; Okayama T; Dohi O; Yoshida N; Kamada K; Uchiyama K; Takagi T; Konishi H; Shiozaki A; Fujiwara H; Konishi H; Naito Y; Teramukai S; Itoh Y
Cancer Sci; 2019 Dec; 110(12):3754-3760. PubMed ID: 31646714
[TBL] [Abstract][Full Text] [Related]
23. [Safety and Efficacy of Neoadjuvant Chemotherapy(UDON: 5-FU, Docetaxel, and Nedaplatin)for Esophageal Cancer].
Konishi T; Komatsu S; Takeda R; Kanazawa H; Soga K; Shimomura K; Ikeda J; Taniguchi F; Shioaki Y
Gan To Kagaku Ryoho; 2023 Dec; 50(13):1381-1383. PubMed ID: 38303281
[TBL] [Abstract][Full Text] [Related]
24. Comparison of preoperative chemotherapy using docetaxel, cisplatin and fluorouracil with cisplatin and fluorouracil in patients with advanced carcinoma of the thoracic esophagus.
Ui T; Fujii H; Hosoya Y; Nagase M; Mieno MN; Mori M; Zuiki T; Saito S; Kurashina K; Haruta H; Matsumoto S; Niki T; Lefor A; Yasuda Y
Dis Esophagus; 2015; 28(2):180-7. PubMed ID: 24529073
[TBL] [Abstract][Full Text] [Related]
25. Preoperative docetaxel, cisplatin, and fluorouracil treatment with pegfilgrastim on day 7 for patients with esophageal cancer: A phase II study.
Maeda O; Fukaya M; Koike M; Miyata K; Kanda M; Nishida K; Ando M; Kodera Y; Ando Y
Asia Pac J Clin Oncol; 2022 Dec; 18(6):578-585. PubMed ID: 35043574
[TBL] [Abstract][Full Text] [Related]
26. Definitive chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) for advanced cervical esophageal cancer.
Okamoto H; Taniyama Y; Sakurai T; Heishi T; Teshima J; Sato C; Maruyama S; Ito K; Onodera Y; Konno-Kumagai T; Ishida H; Kamei T
Esophagus; 2018 Oct; 15(4):281-285. PubMed ID: 29948480
[TBL] [Abstract][Full Text] [Related]
27. Preoperative docetaxel/cisplatin/5-fluorouracil chemotherapy in patients with locally advanced gastro-esophageal adenocarcinoma.
Bayraktar UD; Bayraktar S; Hosein P; Chen E; Koniaris LG; Rocha-Lima CM; Montero AJ
Med Oncol; 2012 Sep; 29(3):1707-10. PubMed ID: 22033912
[TBL] [Abstract][Full Text] [Related]
28. Prognostic Factors for Esophageal Squamous Cell Carcinoma Treated with Neoadjuvant Docetaxel/Cisplatin/5-Fluorouracil Followed by Surgery.
Sugimura K; Miyata H; Shinno N; Ushigome H; Asukai K; Yanagimoto Y; Hasegawa S; Takahashi Y; Yamada D; Yamamoto K; Nishimura J; Motoori M; Wada H; Takahashi H; Yasui M; Omori T; Ohue M; Yano M
Oncology; 2019; 97(6):348-355. PubMed ID: 31461716
[TBL] [Abstract][Full Text] [Related]
29. [Evaluation of efficacy and safety of first-line docetaxel/cisplatin/5-FU combined therapy for advanced esophageal cancer].
Minowa M; Kinoshita Y; Hasebe S; Ito T; Ogawa M; Takebayashi K; Ehara K; Ueno M; Udagawa H; Hayashi M
Gan To Kagaku Ryoho; 2011 Mar; 38(3):393-7. PubMed ID: 21403440
[TBL] [Abstract][Full Text] [Related]
30. Neoadjuvant Chemotherapy with Divided-dose Docetaxel, Cisplatin and Fluorouracil for Patients with Squamous Cell Carcinoma of the Esophagus.
Ojima T; Nakamori M; Nakamura M; Katsuda M; Hayata K; Kato T; Kitadani J; Tabata H; Takeuchi A; Iwahashi M; Yamaue H
Anticancer Res; 2016 Feb; 36(2):829-34. PubMed ID: 26851048
[TBL] [Abstract][Full Text] [Related]
31. [A Case of Resected Advanced Esophageal Cancer That Responded to Combination Therapy Comprising Docetaxel, Cisplatin, and 5-Fluorouracil].
Kuga Y; Kitamura S; Mouri T; Miwata T; Sakimoto H; Nishida T
Gan To Kagaku Ryoho; 2017 Mar; 44(3):247-249. PubMed ID: 28292996
[TBL] [Abstract][Full Text] [Related]
32. Neoadjuvant chemotherapy of triplet regimens of docetaxel/cisplatin/5-FU (DCF NAC) may improve patient prognosis of cStage II/III esophageal squamous cell carcinoma-propensity score analysis.
Yamashita K; Katada N; Moriya H; Hosoda K; Mieno H; Katada C; Koizumi W; Hoshi K; Watanabe M
Gen Thorac Cardiovasc Surg; 2016 Apr; 64(4):209-15. PubMed ID: 26868531
[TBL] [Abstract][Full Text] [Related]
33. The Presence of Serum p53 Antibody Predicts the Pathological Tumor Response to Neoadjuvant Chemotherapy with Docetaxel, Cisplatin and Fluorouracil (DCF) in Esophageal Squamous Cell Carcinoma.
Hiyoshi Y; Yoshida N; Watanabe M; Kurashige J; Baba Y; Sakamoto Y; Baba H
World J Surg; 2017 Feb; 41(2):480-486. PubMed ID: 27637603
[TBL] [Abstract][Full Text] [Related]
34. Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study.
Kim S; François E; André T; Samalin E; Jary M; El Hajbi F; Baba-Hamed N; Pernot S; Kaminsky MC; Bouché O; Desrame J; Zoubir M; Ghiringhelli F; Parzy A; De La Fouchardiere C; Smith D; Deberne M; Spehner L; Badet N; Adotevi O; Anota A; Meurisse A; Vernerey D; Taieb J; Vendrely V; Buecher B; Borg C
Lancet Oncol; 2018 Aug; 19(8):1094-1106. PubMed ID: 30042063
[TBL] [Abstract][Full Text] [Related]
35. Pegfilgrastim for the management of neutropenia during neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in esophageal cancer patients.
Yoshimoto T; Oshima T; Fukada T; Imamura N; Nakanishi T; Ebisutani N; Morishita D; Mieno M; Nakai K; Sei H; Kitayama Y; Eda H; Okugawa T; Tomita T; Fukui H; Shinzaki S
Int J Clin Oncol; 2024 Feb; 29(2):142-148. PubMed ID: 38063978
[TBL] [Abstract][Full Text] [Related]
36. [Current status of neoadjuvant chemotherapy for advanced esophageal cancer].
Tanabe S; Shirakawa Y; Maeda N; Katsube R; Ohara T; Sakurama K; Noma K; Fujiwara T
Gan To Kagaku Ryoho; 2013 Nov; 40(12):1612-4. PubMed ID: 24393865
[TBL] [Abstract][Full Text] [Related]
37. Outcomes of preoperative chemotherapy with docetaxel, cisplatin, and 5-fluorouracil followed by esophagectomy in patients with resectable node-positive esophageal cancer.
Watanabe M; Baba Y; Yoshida N; Ishimoto T; Nagai Y; Iwatsuki M; Iwagami S; Baba H
Ann Surg Oncol; 2014 Sep; 21(9):2838-44. PubMed ID: 24715216
[TBL] [Abstract][Full Text] [Related]
38. Docetaxel plus 5-fluorouracil and cisplatin (DCF) induction chemotherapy for locally advanced borderline-resectable T4 esophageal cancer.
Yokota T; Hatooka S; Ura T; Abe T; Takahari D; Shitara K; Nomura M; Kondo C; Mizota A; Yatabe Y; Shinoda M; Muro K
Anticancer Res; 2011 Oct; 31(10):3535-41. PubMed ID: 21965775
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of pegfilgrastim administration in patients with esophageal cancer treated with docetaxel, cisplatin, and 5-fluorouracil.
Yoshida Y; Komori K; Aoki M; Sandou M; Takagi M; Uejima E
Pharmazie; 2018 Oct; 73(10):613-616. PubMed ID: 30223928
[TBL] [Abstract][Full Text] [Related]
40. ABCB1 and ABCC2 genetic polymorphism as risk factors for neutropenia in esophageal cancer patients treated with docetaxel, cisplatin, and 5-fluorouracil chemotherapy.
Nomura H; Tsuji D; Demachi K; Mochizuki N; Matsuzawa H; Yano T; Daiko H; Fujii S; Kojima T; Itoh K; Kawasaki T
Cancer Chemother Pharmacol; 2020 Aug; 86(2):315-324. PubMed ID: 32748110
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
